Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level. In this population-based study, we included individuals with MS living in the C...

Full description

Saved in:
Bibliographic Details
Published in:BMC health services research 2020-08, Vol.20 (1), p.797-797, Article 797
Main Authors: Moccia, Marcello, Loperto, Ilaria, Lanzillo, Roberta, Capacchione, Antonio, Carotenuto, Antonio, Triassi, Maria, Brescia Morra, Vincenzo, Palladino, Raffaele
Format: Article
Language:English
Subjects:
Adult
Analysis
Care and treatment
Clinical medicine
Comorbidity
Costs
Costs and Cost Analysis - statistics & numerical data
Datasets
Diagnosis
Dosage and administration
Drug dosages
Female
Health care costs
Health care expenditures
Health Resources - economics
Health Resources - statistics & numerical data
Health services
Healthcare resource utilization
Humans
Interferon
Interferon beta
Interferon-beta - economics
Interferon-beta - therapeutic use
Italy
Male
Medical care utilization
Medication Adherence - statistics & numerical data
Middle Aged
Multiple sclerosis
Multiple Sclerosis - drug therapy
Patient admissions
Population
Population-based studies
Prescriptions
Retrospective Studies
Variance analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level. In this population-based study, we included individuals with MS living in the Campania Region of Italy from 2015 to 2017, on treatment with intramuscular Interferon Beta-1a (Avonex® = 618), subcutaneous pegylated Interferon Beta-1a (Plegridy® = 259), subcutaneous Interferon Beta-1a (Rebif® = 1220), and subcutaneous Interferon Beta-1b (Betaferon® = 348; and Extavia® = 69). We recorded healthcare resource utilisation from administrative databases (hospital discharges, drug prescriptions, MS-related outpatients), and derived costs from the Regional formulary. We classified hospital admissions into MS-related and non-MS-related. Persistence (time to switch to other disease modifying treatments (DMTs)), and adherence (medication possession ratio (MPR) = medication supply obtained/medication supply expected during follow-up period) were calculated. Patients treated with Rebif® were younger, when compared with other Interferon Beta formulations (p 
ISSN:1472-6963
1472-6963
DOI:10.1186/s12913-020-05664-x